Biogen

Biogen has agreed to pay $900 million to resolve allegations that it violated federal law by paying kickbacks to doctors in the form of speakers and consulting fees to persuade them to prescribe its multiple sclerosis drugs. Federal prosecutors in Boston say the agreement announced Monday settles a whistleblower lawsuit brought by a former Biogen employee. Under the settlement, Biogen...

Biogen begins layoffs amid Alzheimer’s drug fallout

Biogen is slashing the price of its Alzheimer’s treatment months after the drug debuted to widespread criticism for an initial cost that can reach $56,000 annually

Medicare’s “Part B” outpatient premium will jump by $21.60 a month in 2022, one of the largest increases ever.

Persistent concerns about the first new Alzheimer’s treatment in more than 20 years are curbing access more than four months after regulators approved it.

Down nearly 26% from its 52-week high, Micron could prove to be a solid catch-up trade within the Nasdaq 100, Joule Financial’s Quint Tatro says.

Insurance companies are weighing whether to cover Biogen’s controversial new drug for Alzheimer’s disease, which has an annual cost of $56,000.

A month after approving a controversial new Alzheimer’s drug, the FDA has signed off on new prescribing instructions to limit its use to only patients with early or mild cases of the disease. The acting head of the FDA, Dr. Janet Woodcock, also announced that she was ordering an investigation into whether the agency acted improperly in approving the...

The Food and Drug Administration has approved new prescribing instructions that are likely to limit use of a controversial new Alzheimer’s drug

Doctors are trying to figure out who should get a new treatment for Alzheimer’s disease

The FDA has approved a controversial drug for Alzheimer’s disease developed by Cambridge-based pharmaceutical company Biogen.

More than a year after Biogen held multi-day management meetings that became a global superspreader event in the COVID-19 pandemic, newly released emails show the extent of the fear and confusion among the drug makers’ employees in those early days, as testing shortages, miscommunication from the state and changing guidance from health care professionals plagued the response. The emails also…

One year ago this weekend, more than 100 people from around the world convened at the Boston Marriott Long Wharf hotel for a biotech leadership conference led by the Cambridge-based biotech company Biogen. At the time, the novel coronavirus SARS-CoV-2 was widely known to be circulating. The World Health Organization had already declared the virus and the disease it caused…

A biotech conference held at a Boston hotel in late February that had already been blamed for the initial spread of the coronavirus in eastern Massachusetts has now been tied to hundreds of thousands of cases of the virus globally. The two-day Biogen conference at the Boston Marriott Long Wharf hotel is responsible for infecting as many as 330,000 people…

More than 300,000 coronavirus cases have been linked to a Biogen leadership conference that was held in February at the Marriott Long Wharf in Boston, according to a new study.

Government health advisers have sharply criticized an experimental Alzheimer’s drug

There are now 328 total coronavirus cases in Massachusetts, up 72 from a day earlier. It’s the largest spike since the number of cases jumped from 41 to 92 back on March 10, the same day Gov. Charlie Baker declared a state of emergency. Massachusetts is one of the states in the U.S. with the most coronavirus cases in the…

The governor also announced that small businesses will get disaster relief amidst the coronavirus outbreak.

Biogen, the biotech company behind a cluster of coronavirus cases in Massachusetts and several other U.S. states, is committing $10 million to relief efforts in the commonwealth and elsewhere through its foundation. The $10 million the Biogen Foundation is donating “will be used to address immediate critical needs,” mainly in Massachusetts, North Carolina and Italy, for testing, training and health…

One of the major concerns in Massachusetts is getting more labs for testing.